Annexon Biosciences Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

Annexon Biosciences is a mid-sized biotechnology company based in South San Francisco, California, focused on developing therapies that modulate the immune system by targeting the classical complement pathway. Its work centers on blocking C1q, the initiating molecule of this pathway, with the aim of treating autoimmune, neurodegenerative, and ophthalmic disorders driven by classical complement activation. The company emphasizes a biomarker-driven approach intended to improve the probability that its portfolio reaches technical success. 

Its clinical-stage portfolio includes ANX005, ANX007, and ANX009, with ANX005 administered intravenously, ANX007 intravitreally, and ANX009 subcutaneously. The target patient population comprises individuals affected by classical complement-mediated diseases of the body, brain, and eye. In 2026, Annexon partnered with the GBS/CIDP Foundation International to advance the GBS 110 awareness campaign through the year.

Sign up for free to view info

Company overview Employee directory